The influence of 4G/5G polymorphism in the plasminogen-activator-inhibitor-1 promoter on COVID-19 severity and
Tetiana Yatsenko1,2, Ricardo Rios3, Tatiane Nogueira3
1Department of Research Support Utilizing Bioresource Bank, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Insights
The 4G4G genotype of the 4G/5G plasminogen activator inhibitor-1 (PAI-1) polymorphism is linked to suppressed fibrinolysis in severe COVID-19. The 5G5G genotype is associated with inflammation-induced endothelial dysfunction and fibrinolytic overactivation.
Area of Science:
- Genetics
- Immunology
- Cardiovascular Biology
Background:
- Plasminogen activator inhibitor-1 (PAI-1) is implicated in thrombosis and endothelial dysfunction in severe COVID-19.
- PAI-1 expression is influenced by the +43 G>A and 4G/5G promoter gene polymorphisms.
Purpose of the Study:
- To investigate the impact of PAI-1 gene polymorphisms on COVID-19 severity and endothelial dysfunction.
- To elucidate the mechanistic links between PAI-1 genotypes, fibrinolysis, and inflammation in COVID-19 patients.
Main Methods:
- Analysis of clinical data, sera, and peripheral blood mononuclear cells (PBMCs) from COVID-19 patients.
- Genotyping for +43 G>A and 4G/5G PAI-1 promoter polymorphisms.
- Measurement of fibrinolytic factors, interleukin-1β (IL-1β), and NFκB activation.
Main Results:
- The 4G4G genotype of the 4G/5G polymorphism was associated with high circulating PAI-1, low IL-1β and plasmin levels, and suppressed fibrinolysis.
- NFκB was upregulated in PBMCs of COVID-19 patients with the 4G4G genotype.
- The 5G5G genotype was linked to inflammation-induced endothelial dysfunction and fibrinolytic system overactivation.
Conclusions:
- PAI-1 polymorphisms significantly influence fibrinolytic activity and inflammatory responses in severe COVID-19.
- The 4G4G genotype correlates with impaired fibrinolysis, while the 5G5G genotype is associated with endothelial dysfunction and hyperfibrinolysis.
- Understanding these genetic predispositions may aid in risk stratification and therapeutic strategies for COVID-19.
Introduction:
Plasminogen activator inhibitor-1 (PAI-1) is linked to thrombosis and endothelial dysfunction in severe COVID-19. The +43 G>A PAI-1 and 4G/5G promoter polymorphism can influence PAI-1 expression. The 4G5G PAI-1 promoter gene polymorphism constitutes the 4G4G, 4G5G, and 5G5G genotypes. However, the impact of PAI-1 polymorphisms on disease severity or endothelial dysfunction remains unclear.
Methods:
Clinical data, sera, and peripheral blood mononuclear cells (PBMCs) of COVID-19 patients were studied.
Results:
Comorbidities and clinical biomarkers did not correlate with genotypes in either polymorphism. However, differences between fibrinolytic factors and interleukin-1β (IL-1β) were identified in genotypes of the 4G/5G but not the 43 G>A PAI polymorphism. Patients with the 4G4G genotype of the 4G/5G polymorphism showed high circulating PAI-1, mainly complexed with plasminogen activators, and low IL-1β and plasmin levels, indicating suppressed fibrinolysis. NFκB was upregulated in PBMCs of COVID-19 patients with the 4G4G genotype.
Discussion:
Mechanistically, IL-1β enhanced PAI-1 expression in 4G4G endothelial cells, preventing the generation of plasmin and cleavage products like angiostatin, soluble uPAR, and VCAM1. We identified inflammation-induced endothelial dysfunction coupled with fibrinolytic system overactivation as a risk factor for patients with the 5G5G genotype.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Intracellular Signaling Affects Focal Adhesions
Some...
Anticoagulant Drugs: Low-Molecular-Weight Heparins


